The woman’s symptoms are most likely caused by the intrauterine device (IUD), which is known to increase the intensity and discomfort of periods. Ectopic pregnancy and miscarriage are unlikely as the pregnancy test was negative. A urinary tract infection is also unlikely as the urine dip was normal. Although appendicitis should be considered, it does not explain the vaginal bleeding, and the woman’s normal appetite, lack of fever, and mild examination results do not support this diagnosis.

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

When a patient cannot tolerate taking ACE inhibitors, such as lisinopril, an angiotensin-receptor blocker (ARB) should be offered as an alternative, according to NICE guidelines. This is particularly relevant for patients with a medical history of type 2 diabetes mellitus, as an ACE inhibitor is preferred due to its renal protective and antihypertensive properties. In this case, the patient is likely experiencing a dry cough as a side effect of lisinopril use, which is a common issue with ACE inhibitors. To address this, stopping lisinopril and starting irbesartan is the correct course of action. Unlike ACE inhibitors, ARBs do not cause a buildup of bradykinin in the lungs, which is responsible for the dry cough. It is important to note that reassurance alone is not sufficient, as the dry cough will not settle with time. Additionally, arranging a skin prick allergy test is unnecessary, as the patient is not allergic to lisinopril. While amlodipine may be considered as a second-line treatment option, NICE recommends switching to an ARB first.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Patients with COPD who have frequent exacerbations with sputum production, prolonged exacerbations with sputum production, or hospitalizations from exacerbations may be recommended prophylaxis with oral azithromycin if they are non-smokers and have optimized therapy. Before starting azithromycin, the patient should undergo CT thorax, ECG, liver function testing, and sputum cultures. Amoxicillin is not recommended for prophylaxis in COPD patients. Although doxycycline is one of the mainstay antibiotics used to treat acute exacerbations of COPD, it is not used in prophylactic management according to NICE guidelines. Ramipril is used in the management of pulmonary hypertension, which can occur secondary to COPD, but it is not indicated for a patient who experiences frequent exacerbations like the one in this vignette.

NICE guidelines recommend smoking cessation advice, annual influenza and one-off pneumococcal vaccinations, and pulmonary rehabilitation for COPD patients. Bronchodilator therapy is first-line treatment, with the addition of LABA and LAMA for patients without asthmatic features and LABA, ICS, and LAMA for those with asthmatic features. Theophylline is recommended after trials of bronchodilators or for patients who cannot use inhaled therapy. Azithromycin prophylaxis is recommended in select patients. Mucolytics should be considered for patients with a chronic productive cough. Loop diuretics and long-term oxygen therapy may be used for cor pulmonale. Smoking cessation and long-term oxygen therapy may improve survival in stable COPD patients. Lung volume reduction surgery may be considered in selected patients.

Gout is a crystal arthropathy caused by hyperuricaemia, most commonly affecting middle-aged men. Diagnosis is confirmed by aspiration and examination of joint fluid. Treatment is with high-dose NSAIDs or coxibs initially, followed by allopurinol in the long term. RA presents as an acute monoarticular arthritis in only 10% of cases, and is more common in women between the ages of 35 and 55. Septic arthritis and gonococcal arthritis are bacterial infections that present with a hot, red, swollen joint and constitutional symptoms. Reactive arthritis is a sterile arthritis occurring following an infection, usually presenting as an acute, asymmetrical lower limb arthritis.

Distinguishing Multiple Myeloma from Other Bone Diseases

Multiple Myeloma: A Malignant Disease of Plasma Cells

Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is more common in black Africans and rare in Asians, with a median age of onset over 60. Patients may not show any symptoms and are often diagnosed through routine blood tests. However, they are more susceptible to infections and may have low white blood cell counts. Elevated levels of ESR and CRP are almost always present. Diagnosis is confirmed when two out of three of the following are present: paraproteinaemia or Bence Jones protein, radiological evidence of lytic bone lesions, and an increase in bone marrow plasma cells. Patients may experience bone pain, lethargy, thirst, and anaemia, which are all signs of multiple myeloma.

Calcium Pyrophosphate Arthropathy: Shedding of Crystals into Joints

Calcium pyrophosphate arthropathy, also known as pseudogout, is caused by the shedding of calcium pyrophosphate crystals into the joint. It typically presents as an acute-onset monoarticular arthritis, usually in the knee or wrist. The joint will be hot, red, tender, and swollen. Rhomboid-shaped crystals that are weakly positively birefringent under polarised light will be visible in synovial fluid.

Osteoporosis: Fragility Fractures

Osteoporosis is characterised by fragility fractures, such as vertebral crush fractures, Colles fractures, and fractures of the proximal femur. It is uncommon in men at this age, unless associated with hypogonadism. Anaemia and elevated ESR are not seen in osteoporosis.

Osteoarthritis: Joint Pain and Stiffness

Osteoarthritis presents with joint pain, stiffness, and reduced function. The weight-bearing joints, such as the hip and knee, and the small joints of the hand are commonly affected. Patients do not experience symptoms such as thirst and lethargy, which are due to hypercalcaemia. Blood biochemistry is normal in osteoarthritis.

Paget’s Disease of Bone: Bone Remodelling

Paget’s disease of the bone is rare in individuals under 40 years old. It is characterised by bone pain, deformity, fragility fractures, and complications from nerve compression

Causes of Anaemia in End-Stage Renal Failure Patients

Anaemia is a common complication in patients with end-stage renal failure, primarily due to a decrease in the production of erythropoietin by the kidneys. Other causes of anaemia can include folate and vitamin B12 deficiency, uraemic inhibitors, and reduced half-life of circulating blood cells. The prevalence of anaemia in patients with chronic kidney disease (CKD) increases as eGFR levels decrease, with a prevalence of 12% in CKD patients. Folate deficiency and iron deficiency can also cause anaemia, but in this case, the anaemia is more likely related to poor kidney function. Deficiencies in granulocyte colony-stimulating factor and pyridoxine are less likely causes of anaemia in end-stage renal failure patients.

SGLT-2 inhibitors, such as dapaglifozin, have been linked to a severe and rapidly progressing infection called necrotising fasciitis of the genitalia or perineum, also known as Fournier’s gangrene. This condition is caused by bacterial flora and is more common in diabetic and immunocompromised patients. It can lead to multiple organ failure and sepsis, making early surgical debridement and antibiotics crucial for management. It is important to note that Fournier’s gangrene is a serious adverse effect of SGLT-2 inhibitors, while the other options presented in the question are not associated with this condition.

Understanding SGLT-2 Inhibitors

SGLT-2 inhibitors are medications that work by blocking the action of a protein called sodium-glucose co-transporter 2 (SGLT-2) in the kidneys. This results in a decrease in the amount of glucose that is reabsorbed by the body and an increase in the amount of glucose that is excreted in the urine. Examples of SGLT-2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin.

While SGLT-2 inhibitors can be effective in treating type 2 diabetes mellitus, they can also have some important adverse effects. One of the most common side effects is an increased risk of urinary and genital infections, which can occur due to the increased amount of glucose in the urine. Fournier’s gangrene, a rare but serious bacterial infection of the genital area, has also been reported in some cases.

Another potential complication of SGLT-2 inhibitors is normoglycemic ketoacidosis, a condition in which the body produces high levels of ketones even when blood sugar levels are normal. This can be a serious and potentially life-threatening condition if left untreated. Additionally, there is an increased risk of lower-limb amputation in patients taking SGLT-2 inhibitors, so it is important to closely monitor the feet for any signs of injury or infection.

Despite these potential risks, SGLT-2 inhibitors can also have some positive effects on overall health. Many patients taking these medications experience weight loss, which can be beneficial in managing type 2 diabetes mellitus. As with any medication, it is important to discuss the potential benefits and risks of SGLT-2 inhibitors with a healthcare provider before starting treatment.

Understanding Gonorrhoea: Causes, Symptoms, Microbiology, and Management

Gonorrhoea is a sexually transmitted infection caused by the Gram-negative diplococcus Neisseria gonorrhoeae. It can occur on any mucous membrane surface, including the genitourinary tract, rectum, and pharynx. The incubation period of gonorrhoea is typically 2-5 days. Symptoms in males include urethral discharge and dysuria, while females may experience cervicitis leading to vaginal discharge. Rectal and pharyngeal infections are usually asymptomatic.

Immunisation against gonorrhoea is not possible, and reinfection is common due to antigen variation of type IV pili and Opa proteins. Local complications may develop, including urethral strictures, epididymitis, and salpingitis, which can lead to infertility. Disseminated infection may also occur, with gonococcal infection being the most common cause of septic arthritis in young adults.

Management of gonorrhoea involves the use of antibiotics. Ciprofloxacin used to be the treatment of choice, but there is now increased resistance to it. Cephalosporins are now more widely used, with a single dose of IM ceftriaxone 1g being the new first-line treatment. If ceftriaxone is refused, oral cefixime 400mg + oral azithromycin 2g should be used. Disseminated gonococcal infection (DGI) and gonococcal arthritis may also occur, with symptoms including tenosynovitis, migratory polyarthritis, and dermatitis. Later complications include septic arthritis, endocarditis, and perihepatitis.

Common Diabetes Medications and How They Work

Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, work by inhibiting the enzyme DPP-4, which breaks down hormones that stimulate insulin secretion and suppress glucagon secretion. This leads to increased insulin secretion and decreased glucagon release, helping to regulate blood glucose levels.

α-Glucosidase inhibitors, like acarbose, inhibit enzymes needed to digest carbohydrates, leading to decreased glucose absorption.

Sulfonylureas, such as tolbutamide and gliclazide, stimulate insulin release by inhibiting potassium channels in pancreatic cells.

Non-sulfonylurea insulin secretagogues, like repaglinide and nateglinide, also stimulate insulin release but act on a different binding site of the potassium channels.

Insulin sensitizers, including biguanides like metformin and thiazolidinediones (glitazones), increase glucose uptake by the cells and enhance insulin-dependent enzyme production, respectively.

Understanding the Mechanisms of Common Diabetes Medications

If hydrogen peroxide is not appropriate, topical fusidic acid can be used for impetigo.

Understanding Impetigo: Causes, Symptoms, and Management

Impetigo is a common bacterial skin infection that affects both children and adults. It is caused by either Staphylococcus aureus or Streptococcus pyogenes and can develop anywhere on the body, but lesions tend to occur on the face, flexures, and limbs not covered by clothing. The infection can be a primary infection or a complication of an existing skin condition such as eczema, scabies, or insect bites. Impetigo is highly contagious and can spread through direct contact with discharges from the scabs of an infected person or indirectly through toys, clothing, equipment, and the environment.

The symptoms of impetigo include ‘golden’, crusted skin lesions typically found around the mouth. The infection can be managed with limited, localized disease by using hydrogen peroxide 1% cream or topical antibiotic creams such as fusidic acid or mupirocin. However, if the disease is extensive, oral flucloxacillin or oral erythromycin may be prescribed. It is important to note that MRSA is not susceptible to either fusidic acid or retapamulin, so topical mupirocin should be used in this situation.

Children with impetigo should be excluded from school until the lesions are crusted and healed or 48 hours after commencing antibiotic treatment. It is also important to practice good hygiene, such as washing hands regularly and avoiding close contact with infected individuals, to prevent the spread of impetigo. By understanding the causes, symptoms, and management of impetigo, individuals can take steps to prevent and treat this common bacterial skin infection.